Koninklijke Philips N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
03 jun 2010 - 14:00
Statutaire naam
Koninklijke Philips N.V.
Titel
Philips and RXi Pharmaceuticals sign agreement to jointly research innovative image-guided therapy concepts based on RNAi
Bericht
June 3, 2010
PHILIPS AND RXi PHARMACEUTICALS SIGN AGREEMENT TO JOINTLY RESEARCH INNOVATIVE IMAGE-GUIDED THERAPY CONCEPTS BASED ON RNAi
Eindhoven, the Netherlands and Worcester, Massachusetts, USA – Royal Philips Electronics (NYSE: PHG, AEX: PHI) and RXi Pharmaceuticals Corporation (Nasdaq: RXII), a US-based biopharmaceutical company, today announced that they have entered into a joint research agreement to explore the benefits of combining proprietary technologies from both companies for the targeted delivery of experimental therapeutics based on RNA interference (RNAi).
Compounds based on RNAi represent a promising new class of drugs for the targeted treatment of a number of diseases including cancer and cardiovascular disease. Currently, however, one of the greatest challenges in developing RNAi-based therapeutics is finding ways to deliver them to their target while keeping them fully active. The joint research program between Philips and RXi will address this challenge by exploring, in preclinical studies, the possibility of using RXi’s sd-rxRNA™ (self-delivering rxRNA™) in conjunction with Philips’ ultrasound technology to achieve the targeted delivery and monitoring of RNAi-based compounds in cells.
“As part of Philips’ holistic care cycle approach to patient care, we are constantly exploring novel concepts for the diagnosis, treatment and follow-up of diseases. Our decision to jointly research RNAi-based therapies with RXi is driven by our belief that patient care will ultimately benefit from the combination of novel drugs and advanced medical imaging technologies,” said Henk van Houten, senior vice president of Philips Research and head of the healthcare research program. “The development of ultrasound techniques that could non-invasively trigger the delivery of new drug formats such as RNAi therapeutics at a targeted location opens up exciting possibilities for advancing personalized medicine.”
"The most important technological challenges that need to
Datum laatste update: 21 december 2025